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Background: Women are relatively protected from cardiovascular disease com-
pared with men. Since morbid obesity is an independent risk factor for cardiovascu-
lar disease, the current study investigated whether the association between sex and 
cardiovascular risk factors and outcomes can be demonstrated in subjects suffering 
from morbid obesity.
Materials and methods: Two hundred subjects enrolled in a study on cardiovascular 
risk factors in morbid obesity underwent extensive laboratory screening, carotid in-
tima‐media thickness (cIMT) and pulse wave velocity (PWV) measurements. Gender 
differences were analysed using univariate and multivariable linear regression mod-
els. In addition, the effect of menopause on cIMT and PWV was analysed. Results of 
these models were reported as B coefficients with 95% confidence intervals.
Results: The group consisted of 52 men and 148 women, with a mean age of 41 
(±11.8) years and a mean body mass index (BMI) of 42.7 (±5.2) kg/m2. Both, cIMT 
and PWV were significantly higher in men than in women, although the difference 
in cIMT disappeared after adjustment for covariables such as waist circumference, 
age, high‐density lipoprotein cholesterol and mean arterial pressure. PWV was as-
sociated with sex after adjustments for covariables in morbidly obese patients. 
Postmenopausal women had significantly increased cIMT and PWV when compared 
with premenopausal women.
Conclusion: Sex differences in PWV persist in subjects suffering from morbid obe-
sity. However, no difference was found in cIMT between morbidly obese men and 
women after adjustment for classic cardiovascular risk factors. Premenopausal mor-
bidly obese women are protected for cardiovascular disease when compared with 
postmenopausal morbidly obese women.
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1 |  INTRODUCTION
Even though cardiovascular disease (CVD) is one of the 
major causes of death in both men and women at all ages, the 
prevalence in women is relatively low before menopause.1 
This prevalence approaches similar rates for men and women 
in their seventh decade of life. Women are relatively protected 
against CVD and require a heavier risk factor load before de-
veloping CVD.2 The exact mechanism behind this remark-
able sex differences in CVD is still not fully understood.3
Focusing on classic cardiovascular risk (CVR) factors, 
hypertension and smoking are more prevalent in men than 
in women.1 Women have lower total cholesterol levels4 and 
higher high‐density lipoprotein cholesterol (HDL‐C) values1 
than men. These sex differences in cardiovascular risk factors 
diminish after menopause.1,2,4
When studying outcome measures for subclinical athero-
sclerosis, such as common carotid artery intima‐media thick-
ness (cIMT) measurements or pulse wave velocity (PWV), 
previous studies showed that both cIMT5-8 and PWV9,10 are 
higher in men than in women. These sex differences also de-
crease after menopause.3,5
Obese subjects have increased levels of classic CVR fac-
tors11-13 and higher cIMT and PWV values,14-16 and both 
overall and cardiovascular mortality is higher in obese sub-
jects.17,18 Sex differences in cardiovascular mortality persist 
in different levels of overweight and obesity, although the 
differences may attenuate in obese individuals.19 It is un-
clear whether these sex differences persist in morbidly obese 
subjects. The purpose of this study was to investigate sex 
differences in CVR factors in morbid obese subjects and to 
investigate differences in structural and functional outcome 
measures in terms of cIMT and PWV.
2 |  METHODS
2.1 | Study population
This is a report from the ASSISI study. This prospective 
cohort study aims to investigate the effects of bariatric sur-
gery on CVR factors in morbid obesity and comprises 200 
patients, included in the study between April 2015 and April 
2016. All subjects met the international criteria for bariatric 
surgery,20 that is a BMI of ≥ 40 kg/m2 or a BMI of ≥ 35 kg/
m2 and obesity‐related comorbidity, aged 18 to 65  years. 
This obesity‐related comorbidity includes hypertension, type 
2 diabetes, dyslipidaemia, respiratory disease, severe joint 
disease and severe obesity‐related psychological problems. 
Subjects with a previous cholecystectomy, a previous bariat-
ric procedure, an acute inflammatory disease within 6 weeks 
prior to inclusion or immune‐modulating medication were 
excluded. All data presented here are baseline data, which 
were collected at study entry.
The study was approved by the independent Regional 
Medical Ethical Committee Rotterdam (Maasstad Hospital, 
Rotterdam, The Netherlands, ABR no. NL47891.101.14), 
and all subjects gave written informed consent. The ASSISI 
study is registered in the Dutch Trial Register (NTR5172). 
Reporting of the study conforms to STROBE statement.21
2.2 | Definition of menopause, 
type 2 diabetes, hypertension and 
hypercholesterolaemia
Female subjects were considered postmenopausal based on a 
history of secondary amenorrhoea of ≥ 1 year.22 Women who 
had previously undergone hysterectomy were excluded from 
the analysis in pre‐ and postmenopausal women.
Type 2 diabetes mellitus (T2DM) was defined as a 
HbA1c  ≥  48  mmol/mol (6.5%)23 and/or the use of glu-
cose‐lowering medication. Hypertension was defined by a 
systolic blood pressure > 140 mm Hg, a diastolic blood pres-
sure > 90 mm Hg and/or the use of antihypertensive medi-
cation.24 Hypercholesterolaemia was defined as low‐density 
lipoprotein cholesterol (LDL‐C) levels > 2.5 mmol/L and/or 
the use of lipid‐lowering drugs.24
2.3 | Baseline characteristics
Baseline characteristics were obtained during standard pre-
operative screening by the endocrinologist prior to bariatric 
surgery and included medical history and current medication 
profile. Smoking within 6 months prior to inclusion was con-
sidered “active smoking.” Smoking before these 6  months 
was considered “previous smoking.” Anthropometric char-
acteristics included height, weight, waist circumference and 
blood pressure. The body mass index (in kg/m2) and mean 
arterial pressure (MAP) were calculated.
2.4 | Laboratory measurements
Extensive preoperative laboratory testing was carried out in 
all participants. Freshly drawn blood was used for all clini-
cal and haematological chemistry measurements. C‐reac-
tive protein (CRP), glucose, total cholesterol, HDL‐C and 
triglycerides (TG) were determined using the DxC analyser 
(Beckman Coulter). LDL‐C values were calculated using the 
Friedewald formula. Apo B was determined by rate neph-
elometry using Image analyser (Beckman Coulter). Glycated 
haemoglobin (HbA1c) was measured using an HPLC G8 
analyser (Tosoh Bioscience).
2.5 | Carotid intima‐media thickness (cIMT)
cIMT measurements were performed by one observer, ac-
cording to the consensus guidelines for carotid ultrasound for 
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CVD risk assessment as described previously.25 The measure-
ments were carried out using the ART‐LAB (Esaote, Italy) by 
a trained and experienced sonographer, who was unaware of 
the patient's medical history. Ultrasound scans were performed 
with the patients lying in a supine position with the head resting 
comfortably and the neck slightly hyperextended and rotated 
in the opposite direction of the probe. The ultrasound images 
were obtained from the distal 1 cm of the far wall of each com-
mon carotid artery (CCA) using B‐mode ultrasound producing 
two echogenic lines. These lines represent the combined thick-
ness of the intimal and medial layers of the arterial wall. Each 
CCA has been imaged in three different projections: CCA right 
side 90‐120‐150 and CCA left side 210‐240‐270 degrees. The 
segments were measured semi‐automated in triplicate.
2.6 | Pulse wave velocity (PWV)
PWV measurements were carried out using the Mobil‐O‐
Graph (IEM, Germany) as previously described.26 The 
Mobil‐O‐Graph uses an inflatable cuff to measure the PWV. 
The cuff was placed on the patient's bare left upper arm. Cuff 
size was selected based on the patient's upper arm circum-
ference. Triplicate manual measurements were performed. 
PWV has been calculated by the provided software and was 
expressed in m/s.
2.7 | Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 soft-
ware (SPSS Inc).
Data are given as mean  ±  SD. Skewed variables are 
given in median and interquartile range (IQR). Categorical 
data were described in an absolute number as well as a per-
centage of the total group. Differences between males and 
females were analysed using independent t tests for con-
tinuous data with normal distribution, chi‐squared tests for 
categorical data and independent samples Mann‐Whitney 
U tests for continuous data with non‐normal distribution. 
For statistical analysis, cIMT was defined as the mean of 
the six individual measurements, as described above, and 
PWV was defined as the mean of three individual mea-
surements. Systolic and diastolic blood pressure were in-
tegrated in the mean arterial pressure (MAP), which is the 
sum of 1/3 systolic blood pressure and 2/3 diastolic blood 
pressure.27-29
The associations between cIMT and PWV with sex 
were evaluated with univariate linear regression analysis. 
Since cIMT is a skewed variable logarithmic transforma-
tion was performed on this variable. Within the models, 
this transformed variable is named “log cIMT.” The log 
cIMT showed a normal distribution with skewedness of 
0.414 and a kurtosis of −0.329 and is thereby an appro-
priate dependent variable for the models. Covariables in 
further analyses included age, BMI, waist circumference, 
smoking habit, TG, HDL‐C, LDL‐C, CRP, HbA1c and 
MAP. Correlations between covariables (multicollinear-
ity) were checked for confounding, and interaction effects 
were checked using stratified analysis. Within the regres-
sion model for log cIMT, a significant interaction effect 
was observed between HDL‐C and TG, while waist circum-
ference was a significant confounder. In the PWV model, 
sex and waist circumference interacted. Other confound-
ing factors were ignored in the analyses for having a low 
correlation or small effect on the outcome measures. After 
stratification for the confounder “waist circumference,” the 
association between log cIMT and sex was evaluated with 
multivariable linear regression analysis (model: backwards 
stepwise). The following variables were entered into the 
model: sex, age, BMI, waist circumference, smoking habit, 
TG, HDL‐C, LDL‐C, CRP, HbA1c, MAP and the interac-
tion effect “HDL‐C x TG.” The association between PWV 
and sex was assessed in a multivariable linear regression 
analysis (model: backwards stepwise), including sex, age, 
BMI, waist circumference, smoking habit, TG, HDL‐C, 
LDL‐C, CRP, HbA1c, MAP and the interaction effect “sex 
x waist circumference.”
In addition, the effect of menopausal status in women 
on cIMT as well as PWV was assessed using ANOVA tests 
and univariate and multivariable linear regression analysis 
(model: backwards stepwise). The relationships of cIMT and 
PWV with age in both premenopausal and postmenopausal 
women as well as men were observed using scatterplots with 
LOESS smooth lines (α = 0.50). Due to high correlation with 
menopausal state, we eventually removed age from the mod-
els (spearman's rho 0.770, P < 0.001). No significant con-
founding factors or interaction effects were observed. The 
following variables were entered in both the log cIMT and 
PWV model: menopausal status, smoking habit, waist cir-
cumference, TG, HDL‐C, LDL‐C, CRP, HbA1c and MAP. 
Results of these models were reported as B coefficients with 
95% confidence intervals.
3 |  RESULTS
The total cohort included 200 subjects, 52 men and 148 
women, with a mean age of 41 (±11.8) years and a mean BMI 
of 42.7 (±5.2) kg/m2. Men had a significantly higher waist 
circumference and were more likely to suffer from T2DM 
and myocardial infarction. Systolic and diastolic blood pres-
sure, HbA1c and triglyceride levels were increased in men, 
while HDL‐C, LDL‐C and CRP were significantly higher in 
female subjects. Details are displayed in Table 1.
The median cIMT was measured in 152 study subjects and 
was significantly higher in men than in women (0.638 mm 
(IQR 0.549‐0.735) and 0.529  mm (IQR 0.478‐0.600), 
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respectively, P  <  0.001). Furthermore, median PWV was 
measured in 146 subjects and was also significantly higher in 
men in comparison with women (7.3 m/s (IQR 6.6‐8.0) and 
6.8 m/s (IQR 5.9‐8.0), respectively, P = 0.029) (Figure 1).
Using univariate linear regression, female sex was asso-
ciated with a decrease in log cIMT (Beta: −0.362, adjusted 
R2: 0.125, P < 0.001). In the multiple regression analysis, 
after stratification for the confounder waist circumference, 
age, HDL‐C and MAP were significant contributors to log 
cIMT. After adjustment for age, HDL‐C and mean arterial 
pressure, female sex was no longer significantly associ-
ated with a lower log cIMT in subjects with a relatively 
low waist circumference. Within the subgroup of subjects 
with a waist circumference of 129 cm or higher, it appears 
that female sex gives a decrease of 4.7% in cIMT after ad-
justment for covariables. Additional data are displayed in 
Table 2.
In a univariate analysis, female sex was negatively as-
sociated with PWV (Beta: −0.165, adjusted R2: 0.020, 
P = 0.047). In the multivariable analysis, age, BMI, MAP, 
CRP and HbA1c were significant contributors to PWV. 
Female sex was associated with a lower PWV, when ad-
justed for these variables. Based on the appearance of the 
interaction effect “sex x waist circumference,” the effect 
size of female sex on PWV depended on the waist cir-
cumference. To be more precise; the advantage of women 
over men, in terms of PWV, diminishes with increasing 
waist circumference. Additional data are displayed in 
Table 3.
Among women, there was a non‐linear relation between 
age and both cIMT and PWV with an increased inclination 
of the LOESS smooth line from an age of approximately 
45  years, while this relation in men appeared to be more 
or less linear (Figure 1). The female group consisted of 98 





P‐value52 148 98 45
Age (y) 43.7 (±11.0) 40.6 (±12.0) 0.098b 34.1 (±9.4) 53.4 (±4.2) <0.001b
Medical history (n,%)
Diabetes mellitus type 2 18 (34.6%) 22 (14.9%) 0.002a 10 (10.2%) 11 (24.4%) 0.025a
Hypertension 22 (42.3%) 47 (31.8%) 0.169a 21 (21.4%) 25 (55.6%) <0.001a
Hypercholesterolaemia 15 (28.8%) 43 (29.1%) 0.977a 18 (18.4%) 25 (55.6%) <0.001a
Smoking status 0.273a 0.872a
Active smoker 14 (26.9%) 37 (25.0%) 25 (25.5%) 10 (22.2%)
Previous smoker 20 (38.5%) 42 (28.4%) 27 (27.6%) 14 (31.1%)
Weight (kg) 145 (±20.9) 117 (±16.2) <0.001b 120 (±15.0) 113 (±18.4) 0.025b
Height (m) 1.82 (±0.07) 1.67 (±0.07) <0.001b 1.68 (±0.07) 163 (±0.07) <0.001b
BMI (kg/m2) 43.9 (±6.5) 42.3 (±4.6) 0.100b 42.3 (±4.1) 42.4 (±5.5) 0.904b
Waist circumference (cm) 139 (±12.4) 126 (±11.5) <0.001b 127 (±10) 125 (±14) 0.342b
Systolic blood pressure 
(mm Hg)
145 (±17) 137 (±19) 0.009b 132 (±14) 149 (±20) <0.001b
Diastolic blood pressure 
(mm Hg)
86 (±10) 80 (±9) <0.001b 78 (±9) 83 (±10) 0.002b
Hba1c (mmol/mol) 47 (±18) 42 (±10) 0.035b 40 (±7.2) 45 (±12.5) 0.005b
Triglycerides (mmol/L) 2.69 (1.60‐3.72) 1.63 (1.10‐2.17) <0.001c 1.54 (1.02‐2.08) 1.71 (1.27‐2.27) 0.112c
LDL‐cholesterol (mmol/L) 2.8 (±0.9) 3.2 (±1.0) 0.027b 3.08 (±0.90) 3.41 (±1.09) 0.072b
HDL cholesterol (mmol/L) 1.0 (±0.2) 1.3 (±0.3) <0.001b 1.27 (±0.29) 1.40 (±0.27) 0.010b
Apo B (g/L) 1.12 (±0.31) 1.13 (±0.30) 0.875b 1.10 (±0.28) 1.20 (±0.34) 0.090b
Lipoprotein (a) (mg/L) 143 (45‐314) 211 (85‐575) 0.036c 220 (78‐568) 187 (99‐584) 0.773c
CRP (mg/L) 4 (2‐8) 7 (4‐11) <0.001c 8 (4‐13) 6 (3‐10) 0.164c
Leucocytes (109/L) 8.4 (±2.3) 8.8 (±2.5) 0.450b 9.1 (±2.4) 8.2 (±2.7) 0.033b
aChi‐squared. 
bIndependent t test. 
cIndependent samples Mann‐Whitney U test. 
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premenopausal and 45 postmenopausal women. Five women 
were excluded from further analyses, due to a history of hys-
terectomy. Postmenopausal women were significantly more 
likely to suffer from comorbidities such as T2DM, hyper-
tension and hypercholesterolaemia. Systolic and diastolic 
blood pressure, HbA1c and HDL‐C were significantly higher 
in postmenopausal women, than in premenopausal women 
(Table 1).
Median cIMT was significantly higher in postmeno-
pausal women, when compared with premenopausal 
women (0.591  mm (IQR 0.517‐0.684)) and 0.512  mm (IQR 
0.465‐0.563), respectively, P  <  0.001). Additionally, PWV 
was also significantly higher in postmenopausal women than 
in premenopausal women (8.5 m/s (IQR 8.0‐8.8) and 6.2 m/s 
(IQR 5.6‐6.9), respectively, P < 0.001). Even though no sig-
nificant differences were observed in cIMT between men and 
postmenopausal women, PWV was significantly higher in the 
postmenopausal women than in men (Figure 1).
Postmenopausal state was associated with a higher 
log cIMT in univariate analysis (Beta: 0.363, adjusted R2: 
0.124, P < 0.001) as well as after adjustment for covariables 
(Table 4).
Menopausal status was also positively associated with 
PWV in both univariate linear regression model (Beta: 2.067, 
adjusted R2: 0.542, P < 0.001) and a multivariable regression 
analysis (Table 4).
4 |  DISCUSSION
Sex differences in CVR factors and outcome measures for 
subclinical atherosclerosis do not only exist in lean and 
overweight subjects, but persist in subjects with obesity and 
morbid obesity. Even though obesity is associated with an 
increased risk of cardiovascular disease and mortality, mor-
bidly obese women are still relatively protected in compari-
son to men. However, as previously seen in lean and obese 
women, this advantage appears to diminish in postmenopau-
sal morbidly obese women.
The sex differences in classic CVR factors within 
this study are comparable to previously described differ-
ences1,2,4; men had higher systolic and diastolic blood pres-
sure and increased triglyceride levels, while women had 
higher HDL‐C levels and higher CRP levels. In contrast 
F I G U R E  1  Differences in median cIMT and PWV in women versus men (a + b) and in pre‐ and postmenopausal women versus men (c + d)
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to previous reports,4 women within this cohort had higher 
LDL‐C levels in comparison with men. However, men were 
more likely to suffer from T2DM and the prescription of 
lipid‐lowering drugs is part of the protocolled treatment of 
diabetic patients. This could explain the lower LDL‐C lev-
els in men.
Within this study, cIMT and PWV were used as outcome 
measures for atherosclerosis. Both measures were signifi-
cantly lower in morbidly obese women in comparison with 
morbidly obese men, suggesting an advantage for women 
in terms of CVD and cardiovascular mortality. However, 
after adjustment for covariables, it appeared that cIMT was 
not so much influenced by sex, but by differences in waist 
circumference, age, HDL‐C and MAP. Age is the main con-
tributor to an increase in cIMT. Overall, cIMT is known to 
be lower in lean and overweight women, compared with 
men,5-8 but this difference appears to diminish with in-
creasing weight.30 Unfortunately, our study only included 
morbidly obese subjects and no non‐obese controls. No 
firm statements can be made on the differential effect of 
increasing weight on cIMT in men and women. However, 
obesity has been shown to affect cIMT5,6 negatively and 
within lean subjects cIMT is correlated with BMI.6 It was 
thought that this effect of weight on cIMT may be more 
profound in women than in men,7 but our data do not sup-
port this hypothesis.
In contrast to cIMT, PWV was still associated with sex 
after adjustments for covariables in morbidly obese patients. 
As previously described,31,32 age and blood pressure were the 
main contributors to PWV. In addition, female sex was asso-
ciated with lower PWV, although this effect also depended on 
waist circumference. It has been suggested that sex is a major 
contributor to PWV in lean and overweight subjects33 and 
our data now show that this relationship persists in subjects 
with obesity and morbid obesity.
Women are relatively protected against CVD, but this ad-
vantage diminishes in postmenopausal women.2,34 Hormonal 










































The impact of sex on log cIMT was evaluated with multiple linear regression 
analysis (backward stepwise analysis).
aMale subjects were scored by 0, female subjects were scored by 1. 
T A B L E  3  Impact of sex on arterial stiffness (PWV)
Parameter
PWV
B coefficient (95% CI) P‐value
Constant −0.005 (−1.094; 1.084) 0.993
Female sexa −1.242 (−2.495; 0.011) 0.052
Age 0.083 (0.074; 0.091) <0.001
BMI 0.015 (−0.003; 0,034) 0.100
Mean arterial pressure 0.026 (0.017; 0.034) <0.001
CRP ‐0.013 (−0.027; 0.000) 0.051
HbA1c 0.009 (0.001; 0.016) 0.021
Waist × sex 0.012 (0.002; 0.021) 0.021
The impact of sex on PWV was evaluated with multiple linear regression analy-
sis (backward stepwise analysis).
aMale subjects were scored by 0, female subjects were scored by 1. 
T A B L E  4  Impact of menopausal state on subclinical 













































The impact of menopausal state on log cIMT and PWV was evaluated with 
multiple linear regression analysis (backward stepwise analysis).
aPremenopausal women were scored by 0, postmenopausal women were scored 
by 1. 
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imbalances may play an important role in the development 
of CVD, although some hormone replacement studies do not 
support this hypothesis.34 In general, premenopausal women 
have lower cholesterol, LDL‐C, TG and apo B levels than men 
and higher HDL‐C levels.19 After menopause both LDL‐C 
and total cholesterol increase,19 where HDL‐C shows a small 
decline.1 In our morbidly obese population, the differences in 
CVR profile between pre‐ and postmenopausal women were 
small. Postmenopausal women had a significantly increased 
blood pressure, in agreement with the current literature,2 but 
no disadvantages were seen in the lipid‐associated markers. 
In contrast, HDL‐C was actually higher in postmenopausal 
women in comparison with premenopausal women. Our data 
suggest that the difference in CVR factors between pre‐ and 
postmenopausal women attenuates in morbidly obese subjects.
Within the current study, both cIMT and PWV were sig-
nificantly increased in postmenopausal women compared 
with premenopausal women. These relationships persisted 
after adjustment for covariables. In addition to menopausal 
status, cIMT was mainly determined by HbA1c and MAP, 
whereas PWV was mainly determined by HbA1c, MAP and 
CRP. Age and blood pressure are two of the major determi-
nants of these cardiovascular outcome measures.31,32 We de-
cided to remove age from the multivariable analyses, due to 
the high correlation of age and menopausal status. It can be 
suggested that the differences in cIMT between pre‐ and post-
menopausal women are solely explained by age differences. 
However, Figure 1 reveals that the effect of age on cIMT or 
PWV increases after an age of approximately 45 years, sug-
gesting an effect of menopausal status on top of the effect of 
age. Since menopausal status was the factor of interest and 
since the high correlation suggests that the majority of in-
formation on age was included in the menopausal state, it 
seemed justified to remove age from this analysis. However, 
within this study we cannot differentiate the absolute effect 
of age and the absolute effect of menopause, which is a lim-
itation of this study. The effect of menopausal state on PWV 
may be clinically relevant. However, when not considering 
age as a significant contributor to cIMT, being postmeno-
pausal only increases the cIMT value with 3.7%, making the 
effect on cIMT rather irrelevant. Furthermore, it is important 
to realize that the hormonal effects of menopause may also 
appear in subjects suffering from hormonal disbalances due 
to obesity itself, such as polycystic ovary syndrome (PCOS). 
None of the postmenopausal women were formerly diag-
nosed with PCOS, and all of these women were aged 45 years 
or older. However, we are not informed on the effects of hor-
monal disbalances on cardiovascular risk factors, cIMT and 
PWV in the premenopausal women.
As previously mentioned, the lack of non‐obese control 
patients is one of the limitations of this study. It was previ-
ously suggested that differences in cIMT and PWV diminish 
with increasing weight. With the addition of a non‐obese co-
hort, the relation of weight with cIMT and PWV in different 
weight groups could have been investigated.
Another limitation of this study is the difference in base-
line characteristics between men and women. Multivariable 
linear regression analysis was used to adjust for differences 
in the baseline, in order to be able to make statements on the 
effect of sex on cIMT and PWV. We decided to use mean 
arterial pressure as a marker for hypertension. Since we were 
not informed on the duration of hypertension and the effect 
of treatment within the group of subjects suffering from hy-
pertension, the current mean arterial pressure was the most 
objective parameter on blood pressure effects on cIMT and 
PWV. Due to a small number of subjects within this cohort, 
no available follow‐up data conclusions were drawn on sur-
rogate outcome measures for CVD and not on real clinical 
outcomes such as cardiovascular events. Unfortunately, not 
all subjects within this study underwent cIMT or PWV mea-
surements due to technical problems. Baseline characteristics 
were presented on the entire study group and not on the sub-
groups that underwent cIMT and PWV measurement since 
the entire study group was representative for the groups that 
underwent cIMT and PWV measurements.
In conclusion, commonly described sex differences in car-
diovascular outcome measures, such as cIMT and PWV, per-
sist in morbidly obese subjects. Differences in cIMT cannot 
be explained by sex alone and are mainly related to waist cir-
cumference, age, HDL‐C and MAP. The advantage of women 
over men appears to diminish in morbidly obese women after 
menopause. The advantage in CVR translates into both lower 
cIMT and PWV values for premenopausal women. Morbidly 
obese women are, nevertheless, at higher risk of developing 
CVD then their leaner counterparts.
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